A small study shows baricitinib effectively treats refractory Takayasu arteritis & allows for glucocorticoid reduction with no serious adverse events recorded.
Rheuminations: Confessions of a Former Pepsi Addict
Explore a rheumatologist’s journey to break a soda habit & how it reshaped his clinical approach to patient counseling, craving & the psychology of change.
Peripheral Neuropathy Common Among Patients with Sjögren’s Disease
At this ACR Convergence session, experts discussed the peripheral nervous system involvement with Sjögren’s disease that can have several manifestations.
Make All the Right Moves with Your Practice Financials
Taking the time to understand the financial stats of your practice could help you take steps necessary to improve the practice’s financial viability.
The Great Debate: Ultrasound vs. Temporal Artery Biopsy in Giant Cell Arteritis
In the ACR Convergence 2025 session, Great Debate: Ultrasound vs. Temporal Artery Biopsy in Giant Cell Arteritis, two vasculitis experts went head to head to determine the ideal first test in the diagnosis GCA: ultrasound or biopsy.
The Great Pediatric Debate—Corticosteroids in SLE: Slay or Stay?
Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.
Calcium Pyrophosphate Deposition Disease Diagnosis & Treatment Gaps Remain
CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.
Using Vaccines & Data to Protect the Immunocompromised
At this ACR Convergence 2025 session, experts discussed the importance of vaccinating immunocompromised patients with non-live vaccines.
FDA Approves 2 More Denosumab Biosimilars
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
Effect of DMARDs on Pain Sensitivity in RA
Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.